Clinical trials that were focused on the prognostic significance of c-MET overexpression in BC and its correlation with specific BC subtypes reported controversial results, thus the clinical utility of c-MET evaluation is still unconfirmed [6,10,12,13]. This evidence concerns the gene MET and breast cancer.